Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Manhattan Associates Inc — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.6 (market cap $30.93B), while Manhattan Associates Inc trades at $216.88 (market cap $12.99B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 2.4× Manhattan Associates Inc's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while Manhattan Associates Inc pays none. Which is the better fit depends on your goals.
| GEHC | MANH | |
|---|---|---|
Market Cap | $30.93B | $12.99B |
Volume | 5,033,451 | 546,880 |
Sector | Health | Technology |
52-Week High | $88.16 | $223.76 |
52-Week Low | $59.48 | $120.88 |
Enterprise Value | $39.39B | $12.85B |
Dividend Yield | 0.23% | — |
Typical Hold Time | — | 11 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
MANH trades at $222.71, up 2.21% today, with a bullish technical signal and strong profitability metrics including a 96.38% ROE. Recent earnings have consistently beaten expectations, and the company launched new Editions solutions to expand market access. However, high valuation ratios and a legal investigation pose headwinds.
The outlook remains positive with 80% analyst buy ratings and a $219.25 consensus target, but risks include elevated P/E of 63.81 and potential fiduciary breach concerns. Earnings growth and product innovation are key catalysts, yet investors should weigh valuation against legal and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
